Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845035 | 0.77 | PRKCB (0.45) | PRKCGPRKCBPRKCAGSK3BKCNH2 | |
| SCHEMBL6345530 | 0.75 | MGLL (0.50) | TLR9MGLL | |
| SCHEMBL4849912 | 0.74 | HSP90AA1 (0.58) | PRKCGPRKCBPRKCAGSK3BKCNH2 | |
| SCHEMBL4309645 | 0.73 | CYP11B1 (0.46) | PRKCGPRKCBPRKCAMIFCYP11B1 | |
| SCHEMBL6353474 | 0.73 | MGLL (0.38) | TLR9MGLL | |
| SCHEMBL27519940 | 0.72 | NR4A2 (0.40) | PRKCGPRKCBPRKCAGSK3BKCNH2 | |
| SCHEMBL6344642 | 0.70 | PRKCB (0.49) | PRKCGPRKCBPRKCAGSK3BKCNH2 | |
| SCHEMBL2585474 | 0.69 | HTT (0.47) | PRKCGPRKCBPRKCATLR9MGLL | |
| SCHEMBL6348067 | 0.69 | TLR9 (0.40) | TLR9MGLL | |
| SCHEMBL6344199 | 0.69 | TLR9 (0.40) | TLR9MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329657-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7304060-B2 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050004202-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | ZHANG HAN-CHENG (US) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004202-A1 | Indazolyl-substituted pyrroline compounds as kinase inhibitors | MAP2K2, MAP3K20, MAP2K3 | PRKCG 120/4885PRKCB 40/4885PRKCA 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.